Insider Transactions in Q2 2025 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 07
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,303
-4.69%
|
$26,060
$20.28 P/Share
|
|
Apr 07
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,694
+8.83%
|
-
|
|
Apr 07
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-0.96%
|
$16,020
$20.28 P/Share
|
|
Apr 07
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,726
+3.17%
|
-
|
|
Apr 07
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-4.87%
|
$33,320
$20.28 P/Share
|
|
Apr 07
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,933
+10.31%
|
-
|
|
Apr 07
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
727
-2.56%
|
$14,540
$20.28 P/Share
|
|
Apr 07
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,477
+8.02%
|
-
|
|
Apr 07
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-1.26%
|
$14,680
$20.28 P/Share
|
|
Apr 07
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,498
+4.12%
|
-
|
|
Apr 07
2025
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,832
-4.76%
|
$96,640
$20.28 P/Share
|
|
Apr 07
2025
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,992
+8.96%
|
-
|
|
Apr 01
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
991
-0.88%
|
$20,811
$21.77 P/Share
|
|
Apr 01
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,374
+2.94%
|
-
|
|
Apr 01
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
984
-1.85%
|
$20,664
$21.77 P/Share
|
|
Apr 01
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,352
+6.05%
|
-
|
|
Apr 01
2025
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,321
-2.79%
|
$111,741
$21.77 P/Share
|
|
Apr 01
2025
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,719
+6.36%
|
-
|
|
Apr 01
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,034
-0.64%
|
$21,714
$21.77 P/Share
|
|
Apr 01
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,519
+2.14%
|
-
|
|
Apr 01
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,617
-3.07%
|
$33,957
$21.77 P/Share
|
|
Apr 01
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,342
+6.07%
|
-
|
|
Apr 01
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,084
-3.27%
|
$43,764
$21.77 P/Share
|
|
Apr 01
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,920
+7.33%
|
-
|